Curcumin nanoparticles inhibit corneal neovascularization

Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993–997

Cursiefen C, Chen L, Saint-Geniez M, Hamrah P, Jin Y, Rashid S, Pytowski B, Persaud K, Wu Y, Streilein JW et al (2006) Proc Natl Acad Sci U S A 103:11405–11410

Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18–22

Cursiefen C, Chen L, Borges LP, Jackson D, Cao J, Radziejewski C, D’Amore PA, Dana MR, Wiegand SJ, Streilein JW (2004) VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113:1040–1050

Gong Y, Koh DR (2010) Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model. Cell Tissue Res 339:437–448

Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514–2522

Gan L, Fagerholm P, Palmblad J (2004) Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 82:557–563

Benelli U, Ross JR, Nardi M, Klintworth GK (1997) Corneal neovascularization induced by xenografts or chemical cautery: inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 38:274–282

Hayashi A, Popovich KS, Kim HC, de Juan E (1997) Role of protein tyrosine phosphorylation in rat corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 235:460–467

Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43:245–269

Gonzalez L, Loza RJ, Han KY, Sunoqrot S, Cunningham C, Purta P, Drake J, Jain S, Hong S, Chang JH (2013) Nanotechnology in corneal neovascularization therapy—a review. J Ocul Pharmacol Ther 29:124–134

Sarchahi AA, Maimandi A, Tafti AK, Amani M (2008) Effects of acetylcysteine and dexamethasone on experimental corneal wounds in rabbits. Ophthalmic Res 40:41–48

Guidera AC, Luchs JI, Udell IJ (2001) Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology 108:936–944

Shakiba Y, Mansouri K, Rezaei N, Arshadi D (2009) Corneal neovascularization: molecular events and therapeutic options. Recent Patents Inflamm Allergy Drug Discov 3:221–231

Koenig Y, Bock F, Kruse FE, Stock K, Cursiefen C (2012) Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea 31:887–892

Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115:33–38

Oh JY, Kim MK, Wee WR (2009) Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea 28:1070–1073

Ambati BK, Anand A, Joussen AM, Kuziel WA, Adamis AP, Ambati J (2003) Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci 44:590–593

Ambati BK, Joussen AM, Anand A, Adamis AP, Ambati J (2003) Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea 22:465–467

Lu P, Li L, Liu G, van Rooijen N, Mukaida N, Zhang X (2009) Opposite roles of CCR2 and CX3CR1 macrophages in alkali-induced corneal neovascularization. Cornea 28:562–569

Lan W, Petznick A, Heryati S, Rifada M, Tong L (2012) Nuclear factor-kB: central regulator in ocular surface inflammation and diseases. Ocul Surf 10:137–148

Zhao F, Gong Y, Hu Y, Lu M, Wang J, Dong J, Chen D, Chen L, Fu F, Qiu F (2015) Curcumin and its major metabolites inhibit the inflammatory response induced by lipopolysaccharide: translocation of nuclear factor-κB as potential target. Mol Med Rep 11:3087–3093

Gaudana R, Jwala J, Boddu SH (2009) Recent perspectives in ocular drug delivery. Pharm Res 26:1197–1216

Chang JH, Gabison EE, Kato T (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249

Rawas-Qalaji M, Williams CA (2012) Advances in ocular drug delivery. Curr Eye Res 37:345–356

Guha R, Chowdhury S, Palui H, Mishra A, Basak S, Mandal TK, Hazra S, Konar A (2013) Doxorubicin-loaded MePEG-PCL nanoparticles for prevention of posterior capsular opacification. Nanomedicine (Lond) 8:1415–1428

Qazi Y, Stagg B, Singh N, Singh S, Zhang X, Luo L, Simonis J, Kompella UB, Ambati BK (2012) Nanoparticle-mediated delivery of shRNA. VEGF-A plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci 53:2837–2844

Al-Abd AM, Kim NH, Song SC, Lee SJ, Kuh HJ (2009) A simple HPLC method for doxorubicin in plasma and tissues of nude mice. Arch Pharm Res 32:605–611

Bian F, Zhang MC, Zhu Y (2008) Inhibitory effect of curcumin on corneal neovascularization in vitro and in vivo. Ophthalmologica 222:178–186

Klein R, Lobes LA Jr (1976) Ocular alkali burns in a large urban area. Ann Ophthalmol 8:1185–1189

Morgan SJ (1987) Chemical burns of the eye: causes and management. Br J Ophthalmol 71:854

Huang FC, Chan WK, Moriarty KJ (1998) Novel cytokine release inhibitors. Part I: triterpenes. Bioorg Med Chem Lett 8:1883–1886

Kim JS, Choi JS, Chung SK (2010) The effect of curcumin on corneal neovascularization in rabbit eyes. Curr Eye Res 35:274–280

Sivak JM, Ostriker AC, Woolfenden A, Demirs J, Cepeda R, Long D, Anderson K, Jaffee B (2011) Pharmacologic uncoupling of angiogenesis and inflammation during initiation of pathological corneal neovascularization. J Biol Chem 286:44965–44975

Ma DH, Chen JK, Kim WS, Hao YX, Wu HC, Tsai RJ, Hwang DG, Zhang F (2001) Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularisation. Ophthalmic Res 33:353–362

Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, Flynn E, Byers HR (1998) Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 4:376–383

Gao C, Ding Z, Liang B, Chen N, Cheng D (2003) Study on the effects of curcumin on angiogenesis. Zhong Yao Cai 26:499–502

Gupta SK, Kumar B, Nag TC (2011) Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J Ocul Pharmacol Ther 27:123–130

Anand P, Kunnumakkara AB, New-man RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818